ANIX — Anixa Biosciences Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 715446 ·
Last close
$2.91
Market Cap
$101.16M
52W High
$5.46
52W Low
$2.32
ADV30
359,741
Next earnings
2026-09-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -2,737,000 | -2,606,000 | 15,074,000 | 1,398,000 | 1,873,000 |
| Apr 2026 | 0 | — | -2,647,000 | -2,516,000 | 14,865,000 | 1,477,000 | 1,641,000 |
| Jan 2026 | 0 | — | -2,716,000 | -2,565,000 | 15,233,000 | 1,547,000 | 1,387,000 |
| Oct 2025 | 0 | — | -2,876,000 | -2,695,000 | 16,080,000 | 1,244,000 | 2,130,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,376,000
Investing CF
$2,059,000
Financing CF
$5,220,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-259,364,000
Inventory
—
Receivables
$56,000
ST Investments
$12,466,000
EBIT TTM
$-10,976,000
Pretax Income TTM
$-10,468,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -11,701,000 | -10,927,000 | 16,080,000 | 2,130,000 | 15,161,000 | -7,173,000 |
| Oct 2024 | 0 | -13,831,000 | -12,554,000 | 21,591,000 | 2,703,000 | 19,998,000 | -7,335,000 |
| Oct 2023 | 210,000 | -11,011,000 | -9,811,000 | 25,522,000 | 2,151,000 | 24,337,000 | -6,209,000 |
| Oct 2022 | 0 | -13,875,000 | -13,595,000 | 30,412,000 | 2,212,000 | 29,047,000 | -6,492,000 |
| Oct 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$14,093,000
NetIncome TTM
$-10,034,000
OpCashFlow TTM
—
Assets (Latest)
$14,865,000
Forward EPS
$-0.31
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.91 · call volume: 6 · put volume: 51
Expected Move to 2026-11-20:
±$1.60
(54.98%) —
implied range
$1.31 –
$4.51
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KZIA | KAZIA THERAPEUTICS LTD | $100.79M | $8.82 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $101.93M | $5.27 | — |
| PLYX | Polaryx Therapeutics, Inc. | $99.69M | $2.00 | — |
| AARD | Aardvark Therapeutics, Inc. | $103.08M | $4.71 | — |
| IMUX | IMMUNIC, INC. | $103.15M | $7.56 | — |
News headlines (Yahoo Finance, 1h cache)
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
2026-10-05 12:15 · Yahoo
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
2026-10-01 12:35 · Yahoo
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
2026-09-21 12:45 · Yahoo
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
2026-09-16 13:15 · Yahoo
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-09-11 13:00 · Yahoo
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
2026-09-09 12:35 · Yahoo
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
2026-09-03 12:00 · Yahoo
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
2026-08-24 12:55 · Yahoo
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-18 12:45 · Yahoo
Anixa Biosciences secures Korean patent for breast cancer vaccine
2026-06-30 10:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.